We're in a consolidation pattern. The bio space sector is seeing some headwinds. I believe we could trade between 4.50 and 5 until we get some news. TA is not necessarily the best tale of the tape on small caps as their news driven. Although, the daily chart and tools like the MACD and RSI can help explain accumulation and distribution. Remember folks their is a big difference between trading and investing. If you like the story here and have conviction hold it and potentially add on pullbacks. Regarding all the short bashers / the fact is that people rattling the tree on this board might control .00001% of the float thus there just bullies and nothing more . put them on ignore. Yet, I must admit their are a lot of posts about the stock going to 20 and greater. those are concerning to me as I'm a contrarian by nature. The bottom line is if you did you DD and have true conviction then stay the course. God bless.
looks like we might base above 4 as we await news. Happy New Year.. blessings everyone.
Dips are being bought. Held back. I think Sub 5 days are gone as of Monday. Yet, I'm often wrong just as my wife and son. Have a great weekend everyone. Blessings from Cabo.
Board Members, Upon reading about the newly registered trial on clinical. gov. I contacted Mr. Wiklund from CLDN IR DEPT. Please see his below response. I omitted a couple sentences that were not pertinent to the subject matter. He states as you can read below its normal protocol to test higher dosages to determine potential toxicity levels in a new therapy. As, the current dosage has not shown any safety issues. In my humble opinion this is still a risk on FDA event in April. As, his response to me does not speak to the efficacy in the current trial only the safety profile. Hopefully we will get more information on Tuesday. Please do your own due diligence. Blessings.
I was surprised to find that via Clinical.gov that a 36 person mydicar trial thats gated to start April with a dosage 2.5x that of CUPID.What is extremely concerning is if this is a signal that the efficacy in the current trial end points will be too low for the FDA.
With respect to the higher dose trial, we have not seen any dose limiting toxicities, safety concerns, or lab abnormalities with our current dose. Our DSMB has met four times during the CUPID trial without safety concerns. Proper Drug development then argues to initiate small scale studies to explore what a dose limiting tox may be. Particularly with a novel, first in man, gene therapy.
Fredrik Wiklund Less
thank you. I was referring to partners not investors. Was SUMO included in the phase 1 clinical trials ? or was it done via only using the SERCA compound ?
I believe the author of the below article really captured the story. Yet, he's a making a case for CLDN on the long side. Always do your own due diligence. Never allow someone to make your trading / investing decisions for you. You've worked hard for your capitol. Protect it.
thanks Banman.... I'm adding here as well. I hate to ask a tea leaf question as I don't want to annoy anyone. But, I was thinking based on similar story stocks that CLDN could run to 30- 40 pps prior to announcement then if approved could perhaps get to 75... call me crazy. any thoughts on this weegie board question... lol !
those are planned sells. Very normal for BIO´s. Planned sells are away to subsidize income for executives as salaries are nominal. Stock is close to breaking out.... do your own Due diligence
Is doing you a service by highlighting the inherent risk in any major trial. Instead of blasting him you should thank him, Its called objectivity. Its should be a step in everyone investors due diligence otherwise your just drinking the cool aide and following the tea leaves. Its very possible that CLDN hits a homerun and gets permission to get to market yet why not understand the other side of the opportunity. Blessings everyone and good luck on whatever side of the trade you sit...
The unbinding of data and analysis is done by the FDA not CLDN MGMT. The results are provided in a letter called a CRO. The announcement today is based on approval from the FDA.